Global Hypersensitivity Pneumonitis Market – Overview
According to the American Academy of Allergy, Asthma & Immunology, in 2013, globally, sensitization rates to one or more common allergens among school children is approximately 40%-50% and in 2012, 10.6% children were diagnosed with respiratory allergies. Hypersensitivity pneumonitis is a complex syndrome caused due to exposure to a variety of organic particles. Hypersensitivity pneumonitis is divided into three types, acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis which is based on the based on the duration of the illness. Moreover, increasing prevalence of respiratory diseases, increasing healthcare expenditure, and strong government support for research & development have also contributed to the growth of the market.
Request Sample Copy:
https://www.marketresearchfuture.com/sample_request/4649
On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.
On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.
Global Hypersensitivity Pneumonitis Market – Regional Analysis
America commands the largest market for hypersensitivity pneumonitis majorly due to increasing patient population. On regional basis, the Americas Hypersensitivity pneumonitis market is segmented into two major regions, North America and South America. North America commands the largest market in this region. North America is further segmented into the US and Canada. High healthcare spending, increasing prevalence of the respiratory diseases and government encouragement will boost the market in North America. However, South America shows the fastest growth for the American market owing to the presence of huge opportunities for the development of the market.
The Americas hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users. On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis. On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others. On the basis of end users, the market is segmented into hospital, clinics, and others.
Europe is the second largest market for hypersensitivity pneumonitis, which is followed by Asia Pacific. Availability of funds for research, changing environment conditions and government support for research & development will drive the market.
There are various players operating in the global Hypersensitivity Pneumonitis market, some of the major players are Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Abbott (US) Eli Lilly (U.S.), Bayer Cropscience Ltd. (U.S.)., Sunpharma (India), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), Sanofi (France), and Novo Nordisk (Denmark). and others
Report Details @
https://www.marketresearchfuture.com/reports/hypersensitivity-pneumonitis-market-4649
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.